Novel drugs and therapeutic targets for severe mood disorders (Q34732759)

4 August 2017

1 reference

title

Novel drugs and therapeutic targets for severe mood disorders (English)

1 reference

4 August 2017

Sanjay J Mathew

1

1 reference

4 August 2017

Husseini K Manji

series ordinal

2

1 reference

4 August 2017

Dennis S Charney

series ordinal

3

1 reference

4 August 2017

language of work or name

English

0 references

publication date

2 January 2008

1 reference

4 August 2017

Neuropsychopharmacology

1 reference

4 August 2017

33

1 reference

4 August 2017

9

1 reference

4 August 2017

2080-2092

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1301652

4 August 2017

0 references

cites work

Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

How can drug discovery for psychiatric disorders be improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

New approaches to antidepressant drug discovery: beyond monoamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Hippocampal volume measurement in older adults with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Protein kinase C overactivity impairs prefrontal cortical regulation of working memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

AMPA receptors in the therapeutic management of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

GSK-3: tricks of the trade for a multi-tasking kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Antidepressants and neuroplasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

A neurotrophic model for stress-related mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

The role of dopamine in the pathophysiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Update on the therapeutic potential of PDE4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

The role of substance P in stress and anxiety responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Dysregulation of the fibroblast growth factor system in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Shaggy, the homolog of glycogen synthase kinase 3, controls neuromuscular junction growth in Drosophila.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Psychiatric implications of basic and clinical studies with corticotropin-releasing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Neurobiology of early life stress: nonhuman primate models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Discovering endophenotypes for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

The corticosteroid receptor hypothesis of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

The next generation of PDE4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

The combined dexamethasone/CRH test as a potential surrogate marker in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

A molecular mechanism for the effect of lithium on development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Beyond monoamines: glutamatergic function in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

The cellular neurobiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

The medical management of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

New insights into BDNF function in depression and anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Measurements of the anaplerotic rate in the human cerebral cortex using 13C magnetic resonance spectroscopy and [1-13C] and [2-13C] glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Open-label trial of riluzole in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Circadian genes, rhythms and the biology of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

The midbrain periaqueductal gray and fear extinction: opioid receptor subtype and roles of cyclic AMP, protein kinase A, and mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Elevated Concentrations of CSF Corticotropin-Releasing Factor-Like Immunoreactivity in Depressed Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Neurobiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

The mesolimbic dopamine reward circuit in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Regulation of glycogen synthase kinase-3 in patients with affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Drug development for CNS disorders: strategies for balancing risk and reducing attrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Lower serotonin transporter binding potential in the human brain during major depressive episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Glutamate and depression: clinical and preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

The NMDA receptor as a therapeutic target in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Mania-like behavior induced by disruption of CLOCK

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Clinical studies implementing glutamate neurotransmission in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Targeting an old mechanism in a new disease-protection of glutamatergic dysfunction in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

13C magnetic resonance spectroscopy studies of alterations in glutamate neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

A pathophysiological paradigm for the therapy of psychiatric disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Chronic psychosocial stress in tree shrews: effect of the substance P (NK1 receptor) antagonist L-760735 and clomipramine on endocrine and behavioral parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

From monoamines to genomic targets: a paradigm shift for drug discovery in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

An open-label trial of riluzole in patients with treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Pramipexole for bipolar II depression: a placebo-controlled proof of concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

A double-blind, placebo-controlled study of memantine in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

7 January 2021

A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

7 January 2021

Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

7 January 2021

Brain-derived neurotrophic factor and basic fibroblast growth factor downregulate NMDA receptor function in cerebellar granule cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

7 January 2021

Orbitofrontal cortex function and structure in depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

7 January 2021

What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

7 January 2021

Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

7 January 2021

Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

7 January 2021

Glutamate modulators as novel interventions for mood disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

7 January 2021

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

7 January 2021

Effects of imipramine on serotonergic and beta-adrenergic receptor binding in a realistic animal model of depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

7 January 2021

Riluzole promotes cell survival and neurite outgrowth in rat sensory neurones in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301652

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1301652

1 reference

Dimensions Publication ID

4 August 2017

1044235174

0 references

Fatcat ID

release_yoxwwrmstfawvbze6wzrtkmotu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yoxwwrmstfawvbze6wzrtkmotu

24 November 2022

mapped directly with Wikidata item

1 reference